161 related articles for article (PubMed ID: 27544663)
21. Reproducibility of histologic classification in nonfibrotic myeloproliferative neoplasia.
Koopmans SM; Bot FJ; Lam KH; van Marion AM; de Raeve H; Hebeda KM
Am J Clin Pathol; 2011 Oct; 136(4):618-24. PubMed ID: 21917685
[TBL] [Abstract][Full Text] [Related]
22. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
[TBL] [Abstract][Full Text] [Related]
23. Flow cytometry immunophenotypic analysis of Philadelphia-negative myeloproliferative neoplasms: Correlation with histopathologic features.
Ouyang J; Zheng W; Shen Q; Goswami M; Jorgensen JL; Medeiros LJ; Wang SA
Cytometry B Clin Cytom; 2015; 88(4):236-43. PubMed ID: 25557358
[TBL] [Abstract][Full Text] [Related]
24. The effects of hematopoietic stem cell transplant on splenic extramedullary hematopoiesis in patients with myeloproliferative neoplasm-associated myelofibrosis.
Pizzi M; Gergis U; Chaviano F; Orazi A
Hematol Oncol Stem Cell Ther; 2016 Sep; 9(3):96-104. PubMed ID: 27521149
[TBL] [Abstract][Full Text] [Related]
25. Angiogenesis in chronic myeloproliferative diseases detected by CD34 expression.
Panteli K; Zagorianakou N; Bai M; Katsaraki A; Agnantis NJ; Bourantas K
Eur J Haematol; 2004 Jun; 72(6):410-5. PubMed ID: 15128419
[TBL] [Abstract][Full Text] [Related]
26. Validation of a low-cost modified technique for constructing tissue microarrays for canine mammary tumor analysis.
Silva FB; Leite Jda S; de Mello MF; Ferreira AM
Pathol Res Pract; 2016 Sep; 212(9):783-90. PubMed ID: 27461825
[TBL] [Abstract][Full Text] [Related]
27. Aberrant proplatelet formation in chronic myeloproliferative neoplasms.
Muth M; Büsche G; Bock O; Hussein K; Kreipe H
Leuk Res; 2010 Nov; 34(11):1424-9. PubMed ID: 20430444
[TBL] [Abstract][Full Text] [Related]
28. Construction of tissue micro array from prostate needle biopsies using the vertical clustering re-arrangement technique.
Fridman E; Daya D; Srigley J; Whelan KF; Lu JP; Pinthus JH
Prostate; 2011 Sep; 71(13):1374-81. PubMed ID: 21308718
[TBL] [Abstract][Full Text] [Related]
29. Quantitative interpretation of bone marrow biopsies in MPN-What's the point in a molecular age?
Ryou H; Lomas O; Theissen H; Thomas E; Rittscher J; Royston D
Br J Haematol; 2023 Nov; 203(4):523-535. PubMed ID: 37858962
[TBL] [Abstract][Full Text] [Related]
30. Inability of immunomorphometric assessment of angiogenesis to distinguish primary versus secondary myelofibrosis.
Sharma P; Pati HP; Mishra PC; Dinda AK; Gupta R; Sharma A; Jacob TG
Anal Quant Cytol Histol; 2011 Aug; 33(4):236-44. PubMed ID: 21980629
[TBL] [Abstract][Full Text] [Related]
31. Primary myelofibrosis is the most frequent myeloproliferative neoplasm associated with del(5q): clinicopathologic comparison of del(5q)-positive and -negative cases.
Santana-Davila R; Tefferi A; Holtan SG; Ketterling RP; Dewald GW; Knudson RA; Steensma DP; Chen D; Hoyer JD; Hanson CA
Leuk Res; 2008 Dec; 32(12):1927-30. PubMed ID: 18538839
[TBL] [Abstract][Full Text] [Related]
32. Dkk3 levels in patients with myeloproliferative neoplasms.
Medinger M; Muesser P; Girsberger S; Skoda R; Tzankov A; Buser A; Passweg J; Tsakiris DΑ
Thromb Res; 2014 Feb; 133(2):218-21. PubMed ID: 24309205
[TBL] [Abstract][Full Text] [Related]
33. Mutation specific immunohistochemistry is highly specific for the presence of calreticulin mutations in myeloproliferative neoplasms.
Andrici J; Farzin M; Clarkson A; Sioson L; Sheen A; Watson N; Toon CW; Koleth M; Stevenson W; Gill AJ
Pathology; 2016 Jun; 48(4):319-24. PubMed ID: 27114372
[TBL] [Abstract][Full Text] [Related]
34. Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases.
Dentali F; Ageno W; Rumi E; Casetti I; Poli D; Scoditti U; Maffioli M; di Minno MN; Caramazza D; Pietra D; De Stefano V; Passamonti F
Thromb Res; 2014 Jul; 134(1):41-3. PubMed ID: 24787989
[TBL] [Abstract][Full Text] [Related]
35. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients.
Scherber R; Dueck AC; Johansson P; Barbui T; Barosi G; Vannucchi AM; Passamonti F; Andreasson B; Ferarri ML; Rambaldi A; Samuelsson J; Birgegard G; Tefferi A; Harrison CN; Radia D; Mesa RA
Blood; 2011 Jul; 118(2):401-8. PubMed ID: 21536863
[TBL] [Abstract][Full Text] [Related]
36. Perfusion parameters analysis of the vertebral bone marrow in patients with Ph¹⁻ chronic myeloproliferative neoplasms (Ph(neg) MPN): a dynamic contrast-enhanced MRI (DCE-MRI) study.
Courcoutsakis N; Spanoudaki A; Maris TG; Astrinakis E; Spanoudakis E; Tsatalas C; Prassopoulos P
J Magn Reson Imaging; 2012 Mar; 35(3):696-702. PubMed ID: 22069235
[TBL] [Abstract][Full Text] [Related]
37. Morphological and Immunophenotypical Changes of Human Bone Marrow Adipocytes in Marrow Metastasis and Myelofibrosis.
Dello Spedale Venti M; Palmisano B; Donsante S; Farinacci G; Adotti F; Coletta I; Serafini M; Corsi A; Riminucci M
Front Endocrinol (Lausanne); 2022; 13():882379. PubMed ID: 35757418
[TBL] [Abstract][Full Text] [Related]
38. Calreticulin exon 9 mutations in myeloproliferative neoplasms.
Ha JS; Kim YK
Ann Lab Med; 2015 Jan; 35(1):22-7. PubMed ID: 25553276
[TBL] [Abstract][Full Text] [Related]
39. Validation of 2-mm tissue microarray technology in gastric cancer. Agreement of 2-mm TMAs and full sections for Glut-1 and Hif-1 alpha.
Berlth F; Mönig SP; Schlösser HA; Maus M; Baltin CT; Urbanski A; Drebber U; Bollschweiler E; Hölscher AH; Alakus H
Anticancer Res; 2014 Jul; 34(7):3313-20. PubMed ID: 24982335
[TBL] [Abstract][Full Text] [Related]
40. [LAT (linker for activation of T cells): a useful marker for megakaryocyte evaluation on bone marrow biopsies].
Ungari M; Pellegrini W; Borlenghi E; Marocolo D; Ubiali A; Agazzi C; Pich A; Franco V; Facchetti F
Pathologica; 2002 Dec; 94(6):325-30. PubMed ID: 12540999
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
